HA-1A in septic patients with ARDS: Results from the pivotal trial

L. M. Bigatello, R. E. Greene, C. L. Sprung, E. A. Panacek, R. C. Straube, J. L. Zimmerman, R. J. Maunder, P. N. Lanken, E. Pile-Spellmann, K. S. Stanek, A. Zaslavsky, W. M. Zapol

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Objective: To evaluate the effects of HA-1A, a human monoclonal antiendotoxin antibody, in septic patients with ARDS. Design: Substudy of a multicenter, double-blinded, placebo-controlled trial of HA-1A in septic patients. Patients: 63 septic patients with ARDS at the time of study entry. Intervention: A single intravenous injection of HA-1A (100 mg) or placebo. Results: A quantitative radiographic score, the PaO2/FIO2 ratio and an index of the severity of ARDS did not show a significant difference between the treatment and placebo groups at 3, 5 and 7 days after treatment. The duration of endotracheal intubation did not differ between the two groups. 15 of 30 HA-1A treated patients (50%) and 23 of 33 placebo-treated patients (69.7%) died within 28 days. The daily mortality was always lower in the HA-1A group, but this difference was not statistically significant at 28 days. The 28-day survival curves for the two treatment groups adjusted by covariate analysis were not significantly different (p=0.07). Using logistic regression, a significant independent effect of HA-1A treatment was detected upon the early survival rate at 7 days (p=0.03) but not at 14 and 28 days. Conclusion: A single injection of HA-1A in septic patients with ARDS did not reverse acute respiratory failure or improve long-term survival.

Original languageEnglish (US)
Pages (from-to)328-334
Number of pages7
JournalIntensive Care Medicine
Issue number5
StatePublished - May 1 1994


  • Adult respiratory distress syndrome
  • Anti-endotoxin monoclonal antibodies
  • HA-1A
  • Sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'HA-1A in septic patients with ARDS: Results from the pivotal trial'. Together they form a unique fingerprint.

Cite this